How one cancer researcher turned his own
myeloma diagnosis into an opportunity, giving others the potential for greater control — and better outcomes — over their own care.
Not exact matches
Within weeks of her
diagnosis in 1996, Giusti began disrupting the
myeloma research culture — getting isolated doctors and scientists to share data, and building an unheard - of consortium to develop drugs.
To participate in the study, which concludes in July 2020, patients must be 18 years or older and have a histological - or cytological - proven
diagnosis of a malignancy in the lung, breast, head and neck, genitourinary organs or ovaries or multiple
myeloma.
According to Cancer Research UK, each year Britain
diagnoses 4,000 new
Myeloma cases and 2,500
Myeloma sufferers die.
With multiple
myeloma, most patients live four to seven years from their date of
diagnosis, and most become resistant to chemotherapy drugs over time.
Dr. Rajkumar said other updates to the criteria used to diagnose multiple
myeloma include the use of CT and PET - CT scans to identify bone lesions which will enable more accurate
diagnosis and intervention before fractures or other serious problems arise.
«Our group, which includes more than 180
myeloma researchers worldwide, has updated the definition of multiple
myeloma for diagnostic purposes to include validated biomarkers in addition to the current clinical symptoms used for
diagnosis which include, elevated blood calcium levels, kidney failure, anemia and bone lesions,» said lead author S. Vincent Rajkumar, M.D. a hematologist at Mayo Clinic.
The
diagnosis of multiple
myeloma is made by the presence of elevated abnormal plasma cells in the bone marrow.
Here, we used NGS to characterize the genomic landscape of 418 multiple
myeloma cases at
diagnosis and correlate this with prognosis and classification.
Diagnostic testing confirmed the
diagnosis of multiple
myeloma affecting her liver, spleen and bone marrow.